BioCentury
ARTICLE | Top Story

Express Scripts mulls indication-based pricing in cancer

May 28, 2015 1:47 AM UTC

Express Scripts Holding Co. (NASDAQ:ESRX) is in discussions with manufacturers about indication-based pricing for cancer drugs. Under the model, a drug approved for different indications could have different prices depending on the strength of evidence and the nature of outcomes it produces (see BioCentury, Sept. 1).

Spokesperson David Whitrap said the company introduced the idea of indication-based payments to clients two weeks ago at its Outcomes Symposium, and said clients have been "overwhelmingly supportive" of the approach. ...